The adjunct researcher of the Oxford vaccine Carlos Estévez has affirmed that the clinical trial results that support the safety and efficacy of the vaccine against Covid-19they won’t be around until “late 2021”.
“Not before did we have to have an exacerbated optimism and communicate that we will have the vaccine for sure by December, because the results are expected to be available for end of next yearNor does it seem to me that this is a jug of cold water, “Estévez said in an interview with the chain COPE, in reference to the adverse effect that the Oxford vaccine had on a volunteer and that caused the trials to be paused, which have now been resumed.
As he has recognized, “it is always better than no adverse effects in a study “but it has defended that” it has proceeded in a very adequate and orderly manner, always adhering to international protocols. “
In addition, regarding the announcements that the vaccine would arrive in Spain at the end of this year, the researcher has clarified that one thing is “that the vaccine is manufactured, produced” because in fact “it is already being produced and it is expected that doses are available by the end of the year, “and another thing is the clinical trial results that”endorse efficacy and safety of this vaccine at the time of administering it to the population “.
“I think there have been people in different fields who has rushed a bit perhaps when it comes to ensuring that the vaccine will be administered at the end of the year when the final results of the study will be available at least in the UK, at the end of the summer of next year, “he insisted.
For this reason, he has called on politicians to be “quite cautious” although he understands the “tremendous social pressure” they have. He has also ensured that “The safety of the drug has not been compromised at any time”.
Regarding the efficacy of the vaccine, Carlos Estévez has specified that “no drug is 100% effective” although he has pointed out that in the case of the Covid-19 vaccine “it has been determined that there must be an approximate 50% efficacy”.